journal article·2020-12-05Open access

Magnolol, A Novel Antagonist of Thrombin and PAR-1, Inhibits Thrombin-Induced Connective Tissue Growth Factor (CTGF) Expression in Vascular Smooth Muscle Cells and Ameliorate Pathogenesis of Restenosis in Rats

Wen-Chin Ko, Chia-Ti Tsai, Kai-Cheng Hsu, Yu-Che Cheng, Tony Eight Lin, Yi-Ling Chen, Chuang-Ye Hong, Wan-Jung Lu, Chun-Ming Shih, Ting-Lin Yen

Applied Sciences· Volume 10· Issue 23

Abstract

Restenosis and destructive vascular remodeling are the main reasons for treatment failure in patients undergoing percutaneous coronary intervention (PCI). In this study, we explored the efficacy of magnolol (a traditional Chinese medicine) in the treatment of restenosis. The results of this study showed that the activities of thrombin and PAR-1 (protease-activated receptor 1) were significantly decreased by the treatment of magnolol. Based on protein docking analysis, magnolol exhibits its potential to bind to the PAR-1 active site. In addition, thrombin-induced connective tissue growth factor (CTGF) expression and the upstream of CTGF such as JNK-1 (but not JNK-2), c-Jun, and AP-1 were distinctly inhibited by magnolol (50 μM) in vascular smooth muscle cells (VSMC). For the functional assay, magnolol (50 μM) significantly inhibited the migration of VSMC, and rats treated with magnolol (13 mg/kg/day) after balloon angioplasty has observed a significant reduction in the formation of common arterial neointima. In conclusion, we identified a novel mechanism by which magnolol acts as the thrombin activity inhibitor and may be the PAR-1 antagonist. In accordance with these functions, magnolol could decrease thrombin-induced CTGF expression in VSMCs via PAR-1/JNK-1/AP-1 signaling.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Magnolia and Illicium research · Apelin-related biomedical research · Antiplatelet Therapy and Cardiovascular Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Cardiac Electrophysiology, Department of Cardiovascular Center, Cathay General Hospital, 280 Renai Rd. Sec.4, Taipei City 10630, Taiwan

School of Medicine, College of Medicine, Fu Jen Catholic University, 510, Zhongzheng Rd., Xinzhuang Dist., New Taipei City 242062, Taiwan

Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, 7, Chung Shan S. Rd., Zhongzheng Dist., Taipei City 100225, Taiwan

Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, 250 Wu-Hsing Street, Taipei City 11031, Taiwan

Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, 250 Wu-Hsing Street, Taipei City 11031, Taiwan

Ph.D. Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, 250 Wu-Hsing Street, Taipei City 11031, Taiwan

Proteomics Laboratory, Department of Medical Research, Cathay General Hospital, 280 Renai Rd. Sec.4, Taipei City 10630, Taiwan

Department of Biomedical Sciences and Engineering, National Central University, 300, Zhongda Rd., Zhongli District, Taoyuan City 32001, Taiwan

Department of Internal Medicine, Taipei Municipal Wanfang Hospital, 111, Sec. 3, Xinglong Rd., Wenshan Dist., Taipei City 116081, Taiwan

Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei City 11031, Taiwan

Department of Medical Research, Taipei Medical University Hospital, 252 Wuxing St, Xinyi District, Taipei City 11031, Taiwan

Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei City 11031, Taiwan

Division of Cardiology, Department of Internal Medicine and Cardiovascular Research Center, Taipei Medical University Hospital, 252 Wu-Hsing Street, Taipei City 11031, Taiwan

Department of Medical Research, Cathay General Hospital, 280 Renai Rd. Sec.4, Taipei City 10630, Taiwan

Funding

Cathay General Hospital

References (57)

Show source-provided references
1. A prospective natural-history study of coronary atherosclerosis10.1056/NEJMoa1002358 ↗
2. Mechanisms of Smooth Muscle Cell Proliferation and Endothelial Regeneration After Vascular Injury and Stenting: Approach to Therapy &ndash10.1253/circj.CJ-11-0366 ↗
3. Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: A new aspect in therapy of cardiovascular diseases10.2174/1570161111311040010 ↗
4. Vascular Smooth Muscle Cell Proliferation in Restenosis10.1161/CIRCINTERVENTIONS.110.957332 ↗
5. Extracellular matrix changes in stented human coronary arteries10.1161/01.CIR.0000139337.56084.30 ↗
6. Connective tissue growth factor: Potential role in glomerulosclerosis and tubulointerstitial fibrosis10.1046/j.1523-1755.2000.00301.x ↗
7. Human Connective Tissue Growth Factor Is Expressed in Advanced Atherosclerotic Lesions10.1161/01.CIR.95.4.831 ↗
8. Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves’ orbital fibroblasts10.1038/s41598-018-25370-3 ↗
9. A pyrrole–imidazole polyamide targeting transforming growth factor-β1 inhibits restenosis and preserves endothelialization in the injured artery10.1093/cvr/cvn355 ↗
10. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries10.1161/01.CIR.97.6.581 ↗
11. Thrombin and proliferation of vascular smooth muscle cells10.1161/01.RES.77.4.645 ↗
12. GPCRs Revisited: New Insights Lead to Novel Drugs10.3390/ph4020244 ↗
13. Signal transduction by protease-activated receptors10.1111/j.1476-5381.2010.00705.x ↗
14. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation10.1016/0092-8674(91)90261-V ↗
15. Targeting PAR1: Now What?10.1016/j.tips.2017.05.001 ↗
16. Proteinase-Activated Receptors
17. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology10.1161/01.ATV.0000251995.73307.2d ↗
18. Ranaware, A.M., Banik, K., Deshpande, V., Padmavathi, G., Roy, N.K., Sethi, G., Fan, L., Kumar, A.P., and Kunnumakkara, A.B. (2018). Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer. Int. J. Mol. Sci., 19.10.3390/ijms19082362 ↗
19. Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia10.2174/1567201814666161205131745 ↗
20. Linked magnolol dimer as a selective PPARgamma agonist—Structure-based rational design, synthesis, and bioactivity evaluation10.1038/s41598-017-12628-5 ↗
21. Magnolol induces apoptosis in vascular smooth muscle10.1007/s00210-003-0779-3 ↗
22. Thrombin induced connective tissue growth factor expression in rat vascular smooth muscle cells via the PAR-1/JNK/AP-1 pathway10.1038/aps.2011.178 ↗
23. LeadIT, B. (2019, January 12). Available online: http://www.biosolveit.de/LeadIT.
24. The Protein Data Bank10.1093/nar/28.1.235 ↗
25. Vascular smooth muscle cell proliferation is dependent upon upregulation of mitochondrial transcription factor A (mtTFA) expression in injured rat carotid artery10.1016/j.atherosclerosis.2004.08.029 ↗
26. Thrombin induces endothelial arginase through AP-1 activation10.1152/ajpcell.00466.2009 ↗
27. Thrombin-induced connective tissue growth factor expression in human lung fibroblasts requires the ASK1/JNK/AP-1 pathway10.4049/jimmunol.0801582 ↗
28. AP-1 subunits: Quarrel and harmony among siblings10.1242/jcs.01589 ↗
29. Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase
30. AP-1 function and regulation10.1016/S0955-0674(97)80068-3 ↗
31. The pathogenesis of atherosclerosis: A perspective for the 1990s10.1038/362801a0 ↗
32. Pan, H., Boucher, M., and Kaunelis, D. (2016). PAR-1 Antagonists: An Emerging Antiplatelet Drug Class. CADTH Issues in Emerging Health Technologies, Canadian Agency for Drugs and Technologies in Health.
33. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: Study design and rationale10.1016/j.ahj.2009.07.001 ↗
34. Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor alpha and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells10.1124/jpet.110.175182 ↗
35. Craige, S.M., Chen, K., Blanton, R.M., Keaney, J.F., and Kant, S. (2019). JNK and cardiometabolic dysfunction. BioSci. Rep., 39.10.1042/BSR20190267 ↗
36. c-Jun N-terminal kinase 1 (JNK1) is required for coordination of netrin signaling in axon guidance10.1074/jbc.M112.417881 ↗
37. Signal transduction by tumor necrosis factor mediated by JNK protein kinases
38. Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets10.1182/blood.V94.11.3800 ↗
39. Activation of mitogen-activated protein kinases (ERK/JNK) and AP-1 transcription factor in rat carotid arteries after balloon injury10.1161/01.ATV.17.11.2808 ↗
40. Bone marrow-derived c-jun N-terminal kinase-1 (JNK1) mediates liver regeneration10.1016/j.bbadis.2014.10.011 ↗
41. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice10.1158/0008-5472.CAN-07-6332 ↗
42. Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis10.1210/endo.142.4.8099 ↗
43. Jnk1 Deficiency in Hematopoietic Cells Suppresses Macrophage Apoptosis and Increases Atherosclerosis in Low-Density Lipoprotein Receptor Null Mice10.1161/ATVBAHA.116.307580 ↗
44. Connective tissue growth factor stimulates the proliferation, migration and differentiation of lung fibroblasts during paraquat-induced pulmonary fibrosis10.3892/mmr.2015.3537 ↗
45. CTGF induces tenogenic differentiation and proliferation of adipose-derived stromal cells10.1002/jor.24248 ↗
46. Connective Tissue Growth Factor (CTGF) Is Essential for Self Renewal and Proliferation of Mesenchymal Stromal Cells (MSCs) and Affects Leukemia-Stromal Interactions10.1182/blood.V116.21.3845.3845 ↗
47. Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice10.1016/j.atherosclerosis.2006.06.025 ↗
48. Connective Tissue Growth Factor Inhibition Enhances Cardiac Repair and Limits Fibrosis After Myocardial Infarction10.1016/j.jacbts.2018.10.007 ↗
49. Herbal remedy magnolol suppresses IL-6-induced STAT3 activation and gene expression in endothelial cells10.1038/sj.bjp.0706647 ↗
50. Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics10.1161/ATVBAHA.117.309926 ↗
51. Essential role of Pin1 via STAT3 signalling and mitochondria-dependent pathways in restenosis in type 2 diabetes10.1111/jcmm.12082 ↗
52. Thrombin activates NF-kappa B through thrombin receptor and results in proliferation of vascular smooth muscle cells: Role of thrombin in atherosclerosis and restenosis10.1111/j.1749-6632.1997.tb52024.x ↗
53. Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation10.1254/jphs.FP0050473 ↗
54. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: Subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)10.1016/j.jacc.2013.10.048 ↗
55. Direct thrombin inhibitors10.1111/j.1365-2125.2011.03916.x ↗
56. Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists10.1161/STROKEAHA.112.670604 ↗
57. Insights on the Multifunctional Activities of Magnolol